AbbVie's Migraine Franchise Scored a Big Win. Is This Dividend King a No-Brainer Buy Right Now?

AbbVie (NYSE: ABBV), a pharmaceutical giant, is best known for its work in immunology. Over the decade between 2013 (when it became a stand-alone publicly traded company) and 2023, the drugmaker's biggest growth driver was Humira, a medicine for several autoimmune disorders that was once the world's best-selling drug. Humira lost U.S. patent exclusivity in 2023, but since then, Skyrizi and Rinvoq, two other immunology medicines, have become AbbVie's growth pillars.

However, the healthcare leader does have products in other areas that are performing well. One of them is Qulipta, a migraine treatment. And recently, Qulipta achieved a meaningful clinical win that could help boost its sales over the medium term. What does this mean for AbbVie's prospects? Let's find out.

Missed AI's "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our analysts, we're only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »

Qulipta was first approved in the U.S. in 2021 for the preventive treatment of migraine and later earned a label expansion to treat chronic migraine in adults. AbbVie recently announced top-line results from a Phase 3 clinical trial for the medicine in patients with menstrual migraine. During the study, Qulipta led to a meaningful reduction in migraine days compared with a placebo during the perimenstrual period. That was the primary endpoint. Qulipta also hit all secondary endpoints during the trial (including acute medication use and functional disability) while introducing no new safety signals.

The medicine seems likely to earn a label expansion in this indication, given these results. But how large an opportunity is it? As AbbVie notes, there are no medicines approved specifically for menstrual migraine. According to some estimates, around 12% of Americans experience migraines, and at least 60% of those who menstruate and experience migraines say that they happen around the time of their menstrual cycle. Assuming an even split among migraine patients between people who menstruate and people who don't, we could be looking at a total market opportunity of more than nine million adult patients for Qulipta in this indication in the U.S. Of course, there are some complications.

Even if Qulipta becomes the first medicine approved in this narrow niche, it won't achieve anything close to 100% penetration. Its eventual sales in this market will depend on factors such as health insurance coverage, physician adoption, and how many patients believe their menstrual migraines are severe enough to warrant pharmaceutical management. This subset might be far lower than the total number who experience menstrual migraine. Patients who want treatment might also choose alternatives; there may not be medicines approved specifically for menstrual migraines, but other treatments can help. Still, this clinical win should have a meaningful impact on Qulipta's performance.